Chronic Kidney Diseases, Healthy
Conditions
Brief summary
The purpose of this research is to study the efficacy of ultrasound microvessel imaging for evaluation of Chronic Kidney Disease. Definity is an ultrasound contrast agent currently approved by the FDA for use on the heart, liver, and urinary tract. This study will look at its effectiveness on the kidney.
Interventions
DRUGDefinity
Ultrasound contrast agent administered intravenously
DIAGNOSTIC_TESTSuper-resolution ultrasound imaging
Imaging technology for microvessel imaging. This technology localizes and tracks individual microbubbles (FDA approved ultrasound contrast agents) to map microvessel morphology and flow speed at a spatial resolution about 10 times higher than conventional ultrasound imaging.
Sponsors
Mayo Clinic
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
\- Healthy volunteers or Chronic Kidney Disease (CKD) patients with clinically indicated renal biopsy.
Exclusion criteria
* Subjects lacking capacity to consent. * Vulnerable subjects such as prisoners; pregnant women; nursing mother. * Subjects with history of hypersensitivity allergic reactions to ultrasound contrast agents. * Patients with high-risk cardiac diseases.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Renal cortex microvessel density | Baseline | Super-Resolution Ultrasound Imaging (SRUI) parameters reported in percentage |
| Renal cortex microvessel diameter | Baseline | Super-Resolution Ultrasound Imaging (SRUI) parameters reported in millimeters (mm) |
| Renal blood flow velocity | Baseline | Super-Resolution Ultrasound Imaging (SRUI) parameters reported in centimeters per second (cm/sec) |
Countries
United States
Contacts
PRINCIPAL_INVESTIGATORShigao Chen, PhD
Mayo Clinic
Outcome results
None listed